Business
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the
About this update from Minerva Neurosciences, Inc
[{"type":"text","content":"BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL. The Citizens Life Sciences ConferenceFormat:Company presentationDay/Time: Tuesday, March 10 at 9:35 AM ETWebcast:https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/SKrutqyvQVtnaKJDseE6uU If you are interested in meeting with the Minerva team during the conference, please reach out to your Citizens Bank representative. A replay of the presentation will be available on the Company's Investors & Media Events and Presentations webpage for ninety days following the event. About Minerva Neurosciences Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website. Contacts:Investor inquiries: Frederick AhlholmChief Financial OfficerMinerva Neurosciences, [email protected] Corey Davis, Ph.D.LifeSci Advisors, [email protected] \nSource: Minerva Neurosciences, Inc","length":4632,"tagName":"div"}]